Analysis of genome-wide methylation and gene expression induced by 5-aza-2′-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia

References

• Issa JP. Methylation and prognosis: of molecular clocks and hypermethylator phenotypes. Clin Cancer Res 2003;9:2879–2881.
   PubMedGoogle Scholar
• Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007;128:683–692.
   PubMed Web of Science ®Google Scholar
• Leone G, D'Alò F, Zardo G, Voso MT, Nervi C. Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias. Curr Med Chem 2008;15:1274–1287.
   PubMed Web of Science ®Google Scholar
• Schlesinger Y, Straussman R, Keshet I, et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 2007;39:232–236.
   PubMed Web of Science ®Google Scholar
• Viré E, Brenner C, Deplus R, et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 2006;439:871–874.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10:223–232.
   PubMed Web of Science ®Google Scholar
• Steensma DP, Baer MR, Slack JL, et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol 2009;27:3842–3848.
   PubMed Web of Science ®Google Scholar
• Voso MT, Santini V, Finelli C, et al. Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. Clin Cancer Res 2009;15:5002–5007.
   PubMed Web of Science ®Google Scholar
• Yang H, Hoshino K, Sanchez-Gonzalez B, Kantarjian H, Garcia-Manero G. Antileukemia activity of the combination of 5-aza-2′-deoxycytidine with valproic acid. Leuk Res 2005;29:739–748.
   PubMed Web of Science ®Google Scholar
• Khan R, Schmidt-Mende J, Karimi M, et al. Hypomethylation and apoptosis in 5-azacytidine-treated myeloid cells. Exp Hematol 2008;36:149–157.
   PubMed Web of Science ®Google Scholar
• Flotho C, Claus R, Batz C, et al. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia 2009;23:1019–1028.
   PubMed Web of Science ®Google Scholar
• Soriano AO, Yang H, Faderl S, et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 2007;110:2302–2308.
   PubMed Web of Science ®Google Scholar
• Ozpolat B, Akar U, Zorrilla-Calancha I, Vivas-Mejia P, Acevedo-Alvarez M, Lopez-Berestein G. Death-associated protein 5 (DAP5/p97/NAT1) contributes to retinoic acid-induced granulocytic differentiation and arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Apoptosis 2008;13:915–928.
   PubMed Web of Science ®Google Scholar
• Koschmieder S, D'Alò F, Radomska H, et al. CDDO induces granulocytic differentiation of myeloid leukemic blasts through translational up-regulation of p42 CCAAT enhancer binding protein alpha. Blood 2007;110:3695–3705.
   PubMed Web of Science ®Google Scholar
• Jiang G, Bi K, Tang T, et al. Down-regulation of TRRAP-dependent hTERT and TRRAP-independent CAD activation by Myc/Max contributes to the differentiation of HL60 cells after exposure to DMSO. Int Immunopharmacol 2006;6:1204–1213.
   PubMed Web of Science ®Google Scholar
• Fandy TE, Herman JG, Kerns P, et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 2009;114:2764–2773.
   PubMed Web of Science ®Google Scholar
• Follo MY, Finelli C, Mongiorgi S, et al. Reduction of phosphoinositide-phospholipase C (PI-PLC) beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. Proc Natl Acad Sci USA 2009;29:16811–16816.
   Web of Science ®Google Scholar
• Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292–2230.
   PubMed Web of Science ®Google Scholar
• Voso MT, Scardocci A, Guidi F, et al. Aberrant methylation of DAP-kinase in therapy-related acute myeloid leukemia and myelodysplastic syndromes. Blood 2004;103:698–700.
   PubMed Web of Science ®Google Scholar
• Mikata R, Yokosuka O, Fukai K, et al. Analysis of genes upregulated by the demethylating agent 5-aza-2-deoxycytidine in gastric cancer cell lines. Int J Cancer 2006;119:1616–1622.
   PubMed Web of Science ®Google Scholar
• Weber M, Davies JJ, Wittig D, et al. Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat Genet 2005;37:853–862.
   PubMed Web of Science ®Google Scholar
• Weber M, Hellmann I, Stadler MB, et al. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet 2007;39:457–466.
   PubMed Web of Science ®Google Scholar
• Sadikovic B, Andrews J, Carter D, Robinson J, Rodenhiser DI. Genome-wide H3K9 histone acetylation profiles are altered in benzopyrene-treated MCF7 breast cancer cells. J Biol Chem 2008;283:4051–4060.
   PubMed Web of Science ®Google Scholar
• Dennis G Jr, Sherman BT, Hosack DA, et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 2003;4:P3.
   PubMed Web of Science ®Google Scholar
• Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID Bioinformatics Resources. Nat Protoc 2009;4:44–57.
   PubMed Web of Science ®Google Scholar
• Lee TI, Jenner RG, Boyer LA, et al. Control of developmental regulators by Polycomb in human embryonic stem cells. Cell 2006;21:301–313.
   Web of Science ®Google Scholar
• Simon JA, Kingston RE. Mechanisms of polycomb gene silencing: knowns and unknowns. Nat Rev Mol Cell Biol 2009;10:697–708.
   PubMed Web of Science ®Google Scholar
• Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001;61:3225–3229.
   PubMed Web of Science ®Google Scholar
• Halaban R, Krauthammer M, Pelizzola M, et al. Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications. PloS One 2009;4:e4563.
   PubMed Web of Science ®Google Scholar
• BrackenAP, HelinK, Polycomb group proteins: navigators of lineage pathways led astray in cancer.. Nat Rev Cancer 2009; 9: 773–784.
   PubMed Web of Science ®Google Scholar
• InoharaN, GourleyTS, CarrioR, et al.. Diva, a Bcl-2 homologue that binds directly to Apaf-1 and induces BH3-independent cell death.. J Biol Chem 1998; 273: 32479–32486.
   PubMed Web of Science ®Google Scholar
• KeN, GodzikA, ReedJC, Bcl-B, a novel Bcl-2 family member that differentially binds and regulates Bax and Bak.. J Biol Chem 2001; 20: 12481–12484.
   Web of Science ®Google Scholar
• LucianoF, KrajewskaM, Ortiz-RubioP, et al.. Nur77 converts phenotype of Bcl-B, an antiapoptotic protein expressed in plasma cells and myeloma.. Blood 2007; 109: 3849–3855.
   PubMed Web of Science ®Google Scholar